Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
435 participants
OBSERVATIONAL
2019-03-01
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
NCT04245410
Multivisceral Oncological Resections Involving the Pancreas - An International Multicenter Study
NCT07091097
Investigation of Pancreaticoduodenectomy
NCT03791450
The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer
NCT04902352
Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases
NCT02727179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Definitions:
Diagnosis was based mainly on computed tomography (CT scan), Magnetic Resonance (MRI) and endoscopic ultrasonography (USE) plus biopsy. Surgical technique includes open and laparoscopic approach with or without spleen preservation. Complications were assessed at 90 days using the Clavien - Dindo classification, and those defined as Clavien - Dindo grade IIIA or higher were considered major. For the recording of complications, the medical and nursing notes of the electronic or histories of each patient were consulted. For the specific complications of pancreatic surgery, the definitions of the International Study Group on Pancreatic Surgery (ISGPS) of delayed gastric emptying (21), post-pancreatic hemorrhage (22) and pancreatic fistula were used. The resection margins of the surgical specimen were categorized according to the definitions of the Royal College of Pathologists: R0 (margin to the tumor ≥ 1mm), R1 (margin to the tumor \<1mm) and R2 (macroscopically positive margin) (24). Tumors were staged according to the TNM classification 8 º Ed. (TNM). Follow up scheme was: 6-month outpatient clinic visit during first five years including tumoral markers and CT/MRI. After five years only once a year visit policy was applied.
Variables The following variables were studied: Epidemiological: age, sex, past medical history, medication, Charlson Index and American Society of Anesthesiology (ASA) classification; Clinical: symptoms due to mucinous neoplasm (MCN); Serological tests: leukocytes, amylase; hemoglobin (gr/dl), bilirubin, creatinin, prothrombin time, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9; Radiological/diagnostic: diagnostic tests performed (CT/MRI/EUS), number, size and location of MCN, vascular infiltration (arterial and venous) and preoperative biopsy; Surgical: type of approach (open/laparoscopy/conversion), spleen preservation, associated procedures (organs resected), type of closure of pancreatic remnant, intraoperative bleeding (ml); postoperative course: morbidity and mortality (according to the Clavien-Dindo (CD) classification) (13), pancreatic fistula, postoperative hemorrhage and delayed gastric empting, if present, was classified according to the International Group Study Pancreatic Surgery (IGSPS) classification (14,15), hospital stay and readmissions. The histological data retrieved were TNM: tumor size and lymph nodes harvested and R status. Postoperative follow-up (months) including endocrine and exocrine insufficiency rate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multivisceral resection (MRV)
MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
MVR
Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MVR
Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de Extremadura
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gerardo Blanco-Fernández
Chief of department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
José Manuel Ramia, MD, PhD
Role: STUDY_DIRECTOR
Hospital Universitario de Guadalajara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidad de Extremadura- Facultad de Medicina
Badajoz, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal Pancreatectomy Combined with Multivisceral Resection Is Associated with Postoperative Complication Rates and Survival Comparable to Those After Standard Procedures. J Gastrointest Surg. 2018 Sep;22(9):1549-1556. doi: 10.1007/s11605-018-3804-z. Epub 2018 May 10.
Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK, Cataldegirmen G, Yekebas E, Izbicki JR, Bockhorn M. Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg. 2011 Dec;35(12):2756-63. doi: 10.1007/s00268-011-1263-8.
Panzeri F, Marchegiani G, Malleo G, Malpaga A, Maggino L, Marchese T, Salvia R, Bassi C, Butturini G. Distal pancreatectomy associated with multivisceral resection: results from a single centre experience. Langenbecks Arch Surg. 2017 May;402(3):457-464. doi: 10.1007/s00423-016-1514-0. Epub 2016 Oct 27.
Irani JL, Ashley SW, Brooks DC, Osteen RT, Raut CP, Russell S, Swanson RS, Whang EE, Zinner MJ, Clancy TE. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J Gastrointest Surg. 2008 Dec;12(12):2177-82. doi: 10.1007/s11605-008-0605-9. Epub 2008 Aug 2.
Song KB, Kwon J, Kim YW, Hwang DW, Lee JH, Hong S, Lee JW, Hwang K, Yoo D, Kim SC. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. J Hepatobiliary Pancreat Sci. 2019 Jun;26(6):227-234. doi: 10.1002/jhbp.627. Epub 2019 May 11.
Nikfarjam M, Sehmbey M, Kimchi ET, Gusani NJ, Shereef S, Avella DM, Staveley-O'Carroll KF. Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality. J Gastrointest Surg. 2009 May;13(5):915-21. doi: 10.1007/s11605-009-0801-2. Epub 2009 Feb 7.
Ramia JM, Del Rio-Martin JV, Blanco-Fernandez G, Cantalejo-Diaz M, Rotellar-Sastre F, Sabater-Orti L, Carabias-Hernandez A, Manuel-Vazquez A, Hernandez-Rivera PJ, Jaen-Torrejimeno I, Kalviainen-Mejia HK, Esteban-Gordillo S, Munoz-Forner E, De la Plaza R, Longoria-Dubocq T, De Armas-Conde N, Pardo-Sanchez F, Garces-Albir M, Serradilla-Martin M. Distal pancreatectomy with multivisceral resection: A retrospective multicenter study - Case series. Int J Surg. 2020 Oct;82:123-129. doi: 10.1016/j.ijsu.2020.08.024. Epub 2020 Aug 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UE-CHU 003-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.